Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-0.56%||173.42||0.7%||$1039.49m|
|LLY||Eli Lilly & Co.||2.56%||262.53||1.1%||$683.11m|
|MRK||Merck & Co., Inc.||-1.24%||75.46||0.7%||$655.76m|
|BMY||Bristol-Myers Squibb Co.||-1.24%||68.45||1.0%||$576.62m|
|NRXP||NRX Pharmaceuticals, Inc.||-8.49%||14.66||0.0%||$158.90m|
|NVO||Novo Nordisk A/S||5.49%||98.24||0.1%||$101.33m|
|BHVN||Biohaven Pharmaceutical Holding Co. Ltd.||3.72%||123.20||0.0%||$87.25m|
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. The company product candidate, EB01 is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. EB01 employs a novel, non-steroidal mechanism of action and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in ACD patients. Edesa Biotech was founded on June 12, 2007 and is headquartered in Markham, Canada.